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ABSTRACT
The gastrointestinal tract (GIT) adapts in response to dietary intake and glucocorticoid
dosing through altered villus length, crypt depth, and numbers of proliferating intestinal stem
cells (ISC). The goal was to characterize the impact of glucocorticoids in combination with
different high fat diets on the GIT. Seventy-two juvenile male C57BL/6 mice (n=2-10/group)
were subjected to 4-weeks of dietary intervention (high-fat lard [HFL] vs. high-fat fish-oil
[HFO], with or without prednisolone [40mg/m2/kg] daily). HFO mice had increased villi length
in the duodenum and jejunum while the villi in the ileum were the same across all diets (Chow,
HFO, and HFL). Additionally, both high fats diets had decreased crypt depth in the jejunum and
ileum correlating decreased Ki-67 staining within the crypts. Our data indicates that HFO fed
mice are more sensitive to glucocorticoids. Caution should be taken when consuming a HFO
diet in conjunction with high doses of glucocorticoids.
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INTRODUCTION
Background
Obesity is a global epidemic and in the United States (US) approximately 36% of adults
and 17% of children are obese.1 The National Center for Health Statistics (NCHS) Data Brief
published in November 2015 reports that there have been no significant changes in obesity
prevalence between 2004 and 2013 indicating that obesity rates show no signs of decreasing.1
Dietary intake, specifically the western high fat diet (HFD) consumed in the US, is a contributing
factor to this unwavering epidemic. A typical western HFD is high in calories, ω-6
polyunsaturated fatty acids (PUFA), saturated fats, and simple sugars while being low in fiber
and ω-3 PUFAs.2-4 Consumption of this type of diet promotes diet induced obesity (DIO) leading
to systemic chronic low-grade inflammation which, which is believed to be one of the main
contributing factors to the development of metabolic syndrome (MS). 5-12
MS is characterized by five metabolic markers: central obesity, insulin resistance, high
blood pressure, dyslipidemia, and decreased high density lipoprotein (HDL) cholesterol. MS
effects 30% of the US population and increases the likelihood of developing cardiovascular
disease and type two diabetes mellitus (T2DM) later in life.13 In addition to DIO, certain
populations that are at a greater risk for developing inflammatory driven metabolic disorders,
such as MS, include populations that are treated with chronic high dose synthetic glucocorticoids
(GC).14,15 One such group are the pediatric populations receiving treatment for acute
lymphoblastic leukemia (ALL).14,15
Pediatric ALL is a rapidly developing cancer of the blood and bone marrow and it is the
most prominent cancer in children less than 15 years of age.14,16,17 ALL causes an accumulation
of premature lymphocytes in the blood and bone marrow reducing the production of other white
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blood cells, red blood cells, and platelets.14 Since the 1970’s the survival rate has increased
dramatically to more than 85%, shifting the focus from cancer elimination to reducing
comorbidities and improving quality of life after treatment. The average life expectancy for an
ALL survivor is only 54.7 years of age and the Childhood Cancer Survivor Study found that
73% of pediatric cancer survivors would develop at least one chronic health condition within 30
years after their diagnosis.16,18,19
Many of the adverse metabolic outcomes seen in ALL survivors are thought to be driven,
in part, by chronic GC therapy during treatment.20 GCs were one of the first drugs introduced
into ALL treatment as they have anti-inflammatory effects and are able to induce apoptosis of
thymocytes.21.22 However, chronic exposure to GCs has many negative consequences including
increased visceral adiposity, fatty liver development, weight gain, skeletal muscle loss,
osteoporosis, MS, T2DM, and altered GIT homeostasis.20,23-26
In addition to GCs, ALL treatment consists of a multiagent chemotherapy regimen
including methotrexate (MTX). MTX is antimitotic and does not differentiate between cancer
cells and healthy cells so, all rapidly proliferating cells are affected.27 The rapidly proliferating
cells in the GIT (enterocytes, goblet cells, enteroendocrine cells, and Paneth cells) are decreased
during MTX treatment resulting in a condition called mucositis.28-31 40% of patients receiving
low dose chemotherapies and 100% of patients receiving high dose chemotherapies develop
mucositis.30-32 These patients experience nausea, bloating, ulcers, and diarrhea, unfortunately,
there are no effective clinical treatments for mucositis.28,30,32
Regardless of the metabolic outcomes associated with ALL treatments, the current
nutritional guidelines recommend that ALL patients consume an energy dense diet.14 There is
limited research available on how diet impacts ALL treatment outcomes later, in life but it is
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thought that increased caloric intake along with glucocorticoids contributes to the weight gain
and MS common among ALL survivors.19,33,34 The functional consequences of DIO and MS
have been extensively studied in liver, skeletal muscle, and adipose tissue, however less is
known on the effect in the gastrointestinal tract (GIT).35,36
High Fat Diet and the Gastrointestinal Tract
While adipose tissue is currently known as the main contributor to the inflammation seen
with MS, the GIT has recently been recognized for its inflammatory contributions.12,36,37 This is
in part due to the microbial community present in the GIT. The microbiome can be altered in
response to dietary intake and greatly impacts the development of DIO and MS. 36,38,39 This
impact was seen in germ free mice fed a HFD; they did not become obese until they were
conventionalized with a normal microbiome.40 Conventional mice fed a HFD presented with
increased levels of ileal TNF-α which, preceded weight gain, indicating that intestinal
inflammation may be an early response to a HFD.36,41,42
Additionally, a HFD increases lipopolysaccharide (LPS) presence, a product of gram
negative bacteria in the GIT.43 Mice given a subcutaneous infusion of LPS over 4 weeks had
increased body weight and adiposity mirroring what was seen in mice that were only fed a
HFD.43 This indicates that LPS translocation plays a vital role in the development of the lowgrade inflammation associated with MS.41,44-46
The GIT of healthy individuals has a protective layer of mucous that provides a barrier
between microbes, LPS, and the epithelial cells.47 However, the mucosal layer can be altered by
dietary intake and is compromised when a high fat, high sugar (HF/HS) diet is coupled with low
fiber intake. This leads to a dysbiosis in the microbiome with an increased ratio between grampositive to gram-negative bacteria as Bacteroidetes, a gram-negative bacterium decreases and

3

Firmicutes, a gram-positive bacterium increases. This microbial shift contributes to the
development of DIO and low-grade inflammation as the mucosal layer of GIT thins and LPS
translocation becomes imminent.39,43,48-50
Mucosal layer thinning is partly due to decreased fiber intake causing a reduction of short
chain fatty acid (SCFA) production by bacteria in the GIT and greatly impacts intestinal
permeability.3,12,47,48 A survey in 2012 revealed that the average American consumes
approximately 16 grams of fiber per day while the recommended intake is between 25 and 38
grams per day for women and men, respectively.51 In the colon, dietary fiber can be fermented
by commensal bacteria, producing short chain fatty acids and other metabolites. SCFAs are
essential in the maintenance of the mucosal layer as they promote mucous secretion.3 SCFAs
also attenuate the production of inflammatory cytokines (interleukin beta [IL-b], interleukin six
[IL-6], tumor necrosis factor alpha [TNF-a], and interferon gamma [IFN-g]) and without them,
inflammation is poorly controlled.48,52
Interestingly, a HFD is also associated with reduced levels of small intestinal alkaline
phosphate (IAP), an enzyme that dephosphorylates LPS, making it less potent.52 Thus, the
consumption of a HFD creates a dysbiosis in the microbiome, degrades the mucosal layer, and
decreases IAP allowing LPS to freely act in the GIT. LPS binds to cluster of differentiation 14
(CD14) which, induces ligation of LPS to toll like receptor four (TLR4) on the enterocyte.
TLR4 then activates nuclear factor kappa betta (NFκB) to enhance the expression of
inflammatory molecules: TNF-α, IFN-g, IL-1b, inducible nitric oxide synthase (iNOS), and
cycoloxygnease-2 (COX2).37,53,43,45,54,55 Importantly, CD14 and TLR4 knock out mice do not
present with endotoxemia, obesity, inflammation, or insulin resistance when administered
LPS.10,43
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Another important component of the GIT are tight junctions (TJ) that act as an additional
barrier between epithelial cells near the apical surface preventing luminal bacteria and their
endotoxins, such as LPS, from entering the blood.56 They are maintained by the following
proteins: occulidns, claudins, zonula occulodens, and junction adhesion molecule-A (JAM-A).
TJ proteins play an integral role in maintaining proper intestinal permeability and can also be
altered by diet and inflammatory cytokine production.45,46,49,53,57,58 Increased intestinal
permeability can be seen after seven days on a HFD as evidence by increased fluorescein
isothiocyanate (FITC) labeled dextran in the blood following oral administration.37 This occurs
via decreased expression of TJ proteins due to increased production of TNF-α, IFN-g, and IL-1b
from macrophages.45,46,49,53,58 These inflammatory cytokines can also increase myosin light chain
kinase (MLCK) production, which promotes the contraction of actin and myosin, causing
internalization and TJ alterations.58,59
Dietary intake also impacts GIT morphology through villi and crypt homeostasis.60-62
Mao et al reported a 36.65% increase in jejunal villi length in mice fed a HFD compared to
controls. This correlated with in an increased absorptive area and increased intestinal stem cell
(ISC) proliferation in jejunal crypts indicated by bromodeoxyuradine (BrdU) positive stained
cells.62 Mah et al. had similar results but also found increased crypt density, decreased Paneth
cells in crypts, decreased goblet cells in both crypts and villi and no changes in enteroendocrine
cell levels. This indicates that the increased villi length associated with a HFD is due to
increases in the numbers and of size of absorptive enterocytes.35
One of the mechanisms behind this hyper-proliferative state is the increased amount of
beta-catenin (b-catenin) present when fed a HFD. b-catenin interacts with the Wnt signaling
pathway which is essential for maintaining ISC proliferation within crypts. This pathway is
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regulated by a proteolytic degradation complex consisting of adenomatous polyposis coli, casein
kinase I, glycogen synthase kinase three beta (GSK-3b), and axin. When the complex is
assembled, GSK-3b is inactivated via phosphorylation allowing cytoplasmic b-catenin to
accumulate. This accumulation signals nuclear translocation of the complex and increases bcatenin target genes, such as cyclin D1, which promotes cellular proliferation.62
Paneth cells, which are decreased during a HFD, secrete Wnt3, EGF, and NOTCH
ligands which can provide trophic support to ISC. In vitro studies show a distinct relationship
between Paneth cell loss and decreased ISC proliferation. Interestingly, this data conflicts with
in vivo, suggesting Paneth cells may or may not prevent this hyper-proliferative state.35 Some
show a correlation between Paneth cell reduction and decreased proliferation, while others show
a distinct relationship between a HFD, Paneth cell loss, and decreased proliferation.63-65 An exact
mechanism has yet to be elucidated yet, however peroxisome proliferator activated receptor
beta/delta (PPARb/d) is thought to play a role as it is essential for Paneth cell development.35,65-67
Interestingly, PPARb/d is upregulated with a HFD, indicating that there are additional
components involved with proliferation in vivo.65 Beyaz et al also found that a 60% HFD fed to
mice over a 9-14 month time frame decreases small intestine length, villi length, and increases
crypt depth due to the interactions of PPARb/d, Paneth cells, and ISC proliferation, however he
is alone in these findings.65
Another potential mechanism for this hyper-proliferative state during high fat feeding, is
the increased amount of LPS present due to the dysbiosis in the microbiome.6 LPS can
transactivate the epidermal growth factor receptor leading to the production of COX2.54 COX2 is
a rate limiting enzyme in the synthesis of prostanoids from the ω-6 PUFA arachidonic acid (AA).
COX2 converts AA released from phospholipids by phospholipases to the 2-series of

6

prostaglandins (PGE2), types of prostanoid. Prostaglandins (PGs) play an important role in cell
division, immune responses, and wound healing. PGs derived from AA promote inflammation
by increasing vascular permeability and vasodilation and by directing the synthesis and
migration of proinflammatory cytokines to the site of inflammation.68 Overexpression of COX2
has been implicated in the etiology of many cancers due to the increased synthesis of PGE2 and
inhibition of apoptosis.68,69 PGE2 is also known to amplify its own production by inducing
COX2 expression through G protein coupled EP2 receptor signaling. This positive feedback
amplification is hypothesized to be an important part of sustained proliferation and chronic
inflammatory conditions.68
Glucocorticoids and the Gastrointestinal Tract
Unlike a HFD, GCs promote the normalization of intestinal permeability through
decreased TNF-α production. GCs function by promoting the activation and nuclear
translocation of the glucocorticoid receptor complex allowing it to bind to the glucocorticoid
response element (GRE) of target genes and suppress the expression of MLCK.53 This prevents
TJs from being degraded, ensuring proper intestinal barrier properties.53,70 Quaroni et al. has
shown that IEC-6, normal intestinal epithelial cells from rats, treated with hydrocortisone
occupied a surface area of two to three times larger than untreated cells causing the cell borders
to overlap, leave no intracellular spaces, and form tight junctions.71
When exogenous GCs are administered during embryogenesis or to young animals there
is a marked increase of cellular proliferation in the GIT, specifically the small intestine. This
effect is lost after ~25 days when the GIT is fully formed and functioning. As the intestine loses
its sensitivity to GCs in adulthood there appears to be an inhibitory effect against proliferation, in
some models.72 The evidence for GCs and cellular proliferation is conflicting and much of the
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research has been done using models of cancer or ulcerative colitis where intestinal damage is
already present. Research is limited on the impact of GCs on generally healthy GITs in both
rodents and humans. Additionally, many studies have only focused on acute GC therapy. Little
is known about chronic glucocorticoid use regarding the small intestine.73,74
To rectify this, Gunin et al. studied the impact of acute verses chronic GC treatment in
the jejunum of adult male rats. After three days of treatment there was a decrease of mitotic cells
with no significant differences between BrdU-labeled cells and proliferating cell nuclear antigen
(PCNA) positive cells compared to controls. This indicates that acute glucocorticoid treatment
prolongs all phases of the cell cycle resulting in fewer cells per jejunal crypt. Conversely, when
the jejunum of rats was treated with GCs for either 33 or 63 days, there was a significant increase
in the number mitotic cells compared to controls, as indicated by increased BrdU and PCNA
positively stained cells.72 Thus, chronic GC treatment increases the number of proliferating cells
by quickly exiting the cells from the G0-phase and/or also reducing time spent in all phases in the
cell cycle. Interestingly, despite the increased number of cycling cells, there was still a
significant decrease in the number of cells per jejunal crypt at both 33 and 63 days of treatment.
This may be due to chronic GC treatments also decreasing the lifespan of fully differentiated
cells in the jejunum therefore promoting apoptosis.72 King and Cidlowski also noted this same
phenomenon that increases in proliferation are associated with increased apoptosis since both
processes are regulated, in part, by GCs.75
Another mechanism responsible for glucocorticoid related GIT adaptations is centered
around epidermal growth factor (EGF). GIT integrity is maintained by EGF, which activates
mitogen-activated protein kinases (MAPKs) that are essential in regulating cell proliferation,
migration, and differentiation.76,77 When GCs, specifically dexamethasone, are administered,
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EGF stimulated cell proliferation is inhibited. This prevents extracellular signal-regulated kinase
1 and 2 (ERK1 and 2), members of the MAPK family, from activating and translocating into the
nucleus and increasing c-fos, c-myc, c-jun, and cell cycle activator cyclin D1. This in turn leads
to a decreased production of COX2 which is essential for cell proliferation as indicated by
increased signaling through ERK and p38 MAPK in rats with gastric ulcers who have increased
levels of COX2.77-79
Decreased COX2 expression also leads to decreased PGE2 expression and cell
proliferation.77 Interestingly, cyclin D1 is linked to shortening the G1 phase of the cell cycle
encouraging cells to enter the S phase quicker. Since cyclin D1 is upregulated through ERK
signaling pathways and decreased upon GC administration, it is an important modifiable
component of cell proliferation.77
Fish Oil and the Gastrointestinal Tract
The impact of anti-inflammatory ω-3 PUFAs on the GIT is partly due to their interaction
with the microbiome. ω-3 PUFAs in the form of fish oil promote a healthy ratio of
Bacteroidetes to Firmicutes, unlike a HFD which increases Firmicutes.80 ω -3 fatty acids also
decrease the potency of LPS by replacing the saturated fatty acid side chain with either
docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA).45 While ω-3 fatty acids can make
LPS less potent they also act to decrease LPS translocation into the blood as they maintain
intestinal barrier properties through decreased TNF-α levels.45 Lui et al saw that fish oil
improved intestinal barrier function as indicated by decreased plasma diamine oxidase (DAO)
levels, an intestinal permeability marker, and increased jejunal DAO activity.81 ω-3 PUFAs also
elicit an anti-inflammatory response through G-protein coupled receptor 120 (GPR120) located
on adipocytes, macrophages, and enterocytes.82,83 In macrophages, ω-3 fatty acids activate
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GPR120 to inhibit the actions of LPS and TNF-a, decrease NFκB pro-inflammatory cytokine
production, and increase insulin sensitivity.82
ω-3 PUFAs are considered essential fatty acids because mammals are unable to
synthesize them. Dietary a-linolenic acid (ALA), the precursor form of all ω-3 PUFA, goes
through a series of elongations and desaturations to become the long chain PUFAs:
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).84,85 When ω-3 PUFAs are
consumed, EPA and DHA competitively replace AA in cell membranes. Thus, the PUFA
composition of cell membranes is highly dependent on dietary intake and EPA and DHA
competes with AA not only at the level of incorporation into the cell membrane but also at the
substrate level of the COX pathway generating the 3-series of PG: PGE3. The 2-series of PG,
from ω-6 PUFAs, are mitogenic and pro-inflammatory compared to the 3-series which are antiinflammatory and anti-mitogenic. Interestingly, PGE3 induces COX2 through a similar
mechanism that PGE2 does, but too a much lesser degree therefore decreasing COX2 production
and PGE2 synthesis.68
ω-3 PUFAs research has been focused on the colon due to the anti-mitotic effects ω-3
PUFAs have in colon cancer and irritable bowel syndrome within the GIT.69 EPA and DHA
carry out this effect through different mechanisms; EPA inhibits cell proliferation while DHA
induces apoptosis. Calviello et al. reported that when rats receiving low doses of EPA or DHA
for ten days have decreased cells in the S-phase as indicated by decreased BrdU positive stained
cells in the colon but the average number of cells per crypt remained unchanged.69 Conversely,
the percentage of differentiated cells increased in colon mucosa after DHA and EPA
administration. The number of apoptotic cells was also increased. Acutely, EPA and DHA do
not appear to alter colon morphology but they do inhibit cell proliferation and enhance cell
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differentiation and apoptosis.69 It may be that the intended biological effect of EPA and DHA are
to expand and differentiate the cellular pool which in turn alters cell proliferation and apoptosis
as a homeostatic response.86,87 Additionally, this impact of EPA and DHA may be due to a
decrease of AA in cell membranes induced by EPA and DHA supplementation.69
Turk et al. described that both EPA and DHA prevent the wound triggered transactivation
of EGFR leading to decreased levels of COX2 and decreased healing in a colon damaged by
DSS when compared to mice fed a corn oil diet. There was significant reduction in cellular
proliferation yet no alterations in apoptosis on the EPA and DHA diets. This is potentially due to
the decreased inflammatory cytokines to initiate the repair process in response to damaged
mucosa. Thus, when damage is present in the GIT the anti-mitotic effects of EPA and DHA
appear to be amplified.84
While EPA and DHA are known to be anti-mitotic in the colon, Lui et al found that pigs
fed a fish oil diet had increased villi length in the jejunum and ileum compared to pigs on a corn
oil, high in ω-6 PUFAs, diet. There were no significant differences in crypt depth. Additionally,
when the pigs were challenged with LPS, pigs on the fish oil diet had significantly lower levels
of TNF-a and PGE2 in the jejunum and ileum compared to the corn oil diet. This demonstrates
the anti-inflammatory impact of fish oil in the presence of an inflammatory trigger however,
there is little explanation for the increased villi length.88 More research is necessary to
understand the complex interplay between fatty acid composition of the diet and intestinal
adaptation.
Study Aims
Aim 1: Determine the impact of a 45% high fat diet rich in ω-6 PUFAs and 45% high fat diet
rich in ω-3 PUFAs on small intestinal morphology.
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Aim 2: Determine intestinal morphological alterations induced by orally administered
glucocorticoids when consuming the different high fat diets.
MATERIAL AND METHODS
Animals and Diets
All experiments were performed in accordance with the University of Memphis (UM)
and IACUC guidelines. All housing and experimental procedures were in accordance with the
8th edition of the Guide for the Care and Use of Laboratory Animals, and were approved by The
University’s Institutional Animal Care and Use Committee was obtained. C57BL/6 breeder
pairs were purchased from Envigo Laboratories, Inc. (Indianapolis, IN) and bred on UM campus.
Only male progeny were used for these experiments. Mice were kept on a 12h light/dark cycle
(7AM-7PM) and had access to food and water ad libitum.
Experimental diets were purchased from Research Diets, Inc. (New Brunswick, NJ) and
consisted of the following: high fat lard (HFL [ 20% protein, 35% carbohydrates, 45%fat, ω-6:
ω-3 ratio of 13:1]) and high fat fish oil (HFO [20% protein, 35% carbohydrates, 45% fat, ω-6: ω3 ratio of 1:4]). The HFL and HFO diets were identical in overall composition, but differed only
in their fatty acid profiles (Table-1). Control mice consumed a standard rodent chow (Teklad
2018, Chow [58%carbohydrates, 24%protein, 18%fat]).
Mice were weaned three weeks after birth and randomly distributed to the Chow or HFL
diet. At five weeks of age, the mice were placed in individual cages and began receiving 0.2-0.3
g of pureed sweet potatoes daily for a one week entrainment period. At six weeks of age half of
the mice on the HFL were diet switched to the HFO diet. Mice in the HFL and HFO group were
then further distributed into HFL with glucocorticoids (HFL GC+), HFL without glucocorticoids
(HFL GC-), HFO with glucocorticoids (HFO GC-), and HFO without glucocorticoids (HFO
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GC+). Additionally, mice originally weaned onto the Chow diet at three weeks old were split
into two groups, Chow with glucocorticoids (Chow GC+) and Chow without glucocorticoids
(Chow GC-). The pureed sweet potato was used as the vehicle for oral glucocorticoid
administration. To make this study translationally relevant, the drug treatment protocol
mimicked the treatment protocol of pediatric ALL patients. Specifically, the mice received
40mg/m2/day of prednisolone for 28 days, similar to the dose and time of glucocorticoids given
to pediatric ALL patients. After 4 weeks of intervention, glucose tolerance tests were performed
and blood was collected for biochemical analysis. The mice were euthanized using a carbon
dioxide (CO2) chamber and tissues were harvested (Figure 1).
Sweet potatoes Prednisolone
0.2-0.3 g/day
40 mg/m2/day
Wean
3 weeks

GTT
5 Weeks

8 Weeks

6 Weeks

GTT/
Euthanasia
10 Weeks

Chow GC -

Chow

Chow GC +
HFL GC HFL GC +

HFL

HFO GC HFO GC +

Figure 1; Experimental design. At three weeks of age the male C57BL6 mice were weaned
onto Chow and HFL diets. At 6 weeks, dietary intervention and prednisolone treatment
(40mg/m2/day) started for 28 days (4 weeks). Mice were euthanized at 10 weeks of age.
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Table 1; Composition of experimental diets. HFL n-6 with 45% kcals from lard; HFO n-3 with
45% kcals from menhaden oil.
Ingredients
Protein
Carbohydrate
Fat
Total
kcal/g
Casein, 80 Mesh
L-Cysteine
Sucrose
Corn Starch
Maltodextrin 10
Cellulose, BW200
Soybean Oil
Lard
Menhaden Oil (200 ppm tBHQ)
tBHQ
Mineral Mix S10026
Vitamin Mix V10001
Choline Bitartrate
Cholesterol

HFL n-6
gm (%) kcal (%)
24
20
41
35
24
45
100
4.72
200
800
3
12
172.8
691
72.8
291
100.0
400
50
0
25
225
177.5
1598
0
0
0.0355 0
10
0
10
40
2
0
0.58
0

HFO n-3
gm (%) kcal (%)
24
20
41
35
24
45
100
4.72
200
800
3
12
172.8
691
72.8
291
100.0
400
50
0
25
225
0
0
177.5
1598
0
0
10
0
10
40
2
0
0
0

Lard
Menhaden Oil, ARBP-F
Soybean Oil
Total
C14, Myristic
C16:1, Palmitoleic
C18, Stearic
C18:2, Linoleic
C18:3, Linolenic, n3
C18:4, Stearidonic, n3
C20, Arachidic
C20:4, Arachidonic, n6
C20:4, n3
C20:5, Eicosapentaenoic, n3
C22:5, Docosapentaenoic, n3
C22:5, n6
C22:6, Docosahexaenoic, n3
Total
Saturated
Monounsaturated (g)
Polyunsaturated (g)
ω-6 (g)
ω-3 (g)
ω-6/ω-3 ratio

177.5
0
25
202.5
2.1
2.5
19.8
56.2
4.2
0
0.4
0.5
0
0
0.2
0
0
190.7
60.2
31.6
67.7
35.5
62.8
32.9
57.0
4.4
12.9:1 (~13:1)

0
177.5
25
202.5
14.0
17.7
6.6
16.1
4.3
6.0
0.3
0
3.1
23.3
4.1
0.6
29.0
189.6
59.8
31.5
41.3
21.8
88.5
46.7
17.9
66.6
1:3.7 (~1:4)
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Tissue Collection and Histology
After euthanasia, adipose tissue, muscle, liver, and small intestine were collected and placed
in 10% buffered formalin phosphate for 48 hours before being processed in a Shandon Citadel
2000 Tissue Processor with the following protocol: PBS 3x30 minutes (mins), 50% ethanol 10
mins, 70% ethanol 20 mins, 95% ethanol 3x35 mins, 100% ethanol 3x40 mins, 1:1 ethanol:
xylene 25 min, 1:2 ethanol: xylene 20 min, 100% xylene 40 min, 2:1 xylene: paraffin 30 min, 1:2
xylene: paraffin 30 min, and 100% paraffin 1 hour.
Processed tissues were then embedded in Paraplast X-tra (Leica Biosystems) using the Leica
EG 1160 embedding unit. Embedded tissues were cut into 5 micrometer (µm) thick sections on
the Microm HM 315 and placed onto a 45°C water bath. The sections were mounted onto
uncharged uncoated glass slides. After an overnight drying process the tissue sections were
stained with hematoxylin and eosin by the Leica Autostainer XL ST5010 with the following
protocol: xylene 2x5 mins, 100% ethanol 2x 5 mins, 95% ethanol 5 mins, hematoxylin 5 mins,
DI water 2 mins, water 5 mins, eosin 30 seconds, 95% ethanol 3x5 mins, 100% ethanol 3x10
mins, and xylene 2x5 mins. Coverslip were placed on slides using Permount mounting medium.
Images of the stained slides were captured on a bright field microscope, Ziess Axio
Imager M2, connected to a computer via Zeiss AxioCam MRc. Morphological differences (villi
length, crypt depth, and surface area) were analyzed using the following software: Axio vision
and ImageJ. Villus length and crypt depth were measured in µm on 10X magnified images, with
12 measurements recorded for the duodenum, jejunum, and ileum per mouse and the results of
each were averaged per group (Chow GC+, Chow GC-, HFL GC+, HFL GC-, HFO GC+, and
HFO GC-). Villus length was measured from the base of the villus as indicated by the top of the
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crypt, up to the tip of the villus. Crypt depth was measured from the base of the crypt to the top
of the crypt (Figure 2A).
Surface area was calculated by utilizing the following measurements: small intestine
diameter, villus length, villus width, and the distance between villus. The surface area was then
calculated as follows: from the diameter (D) of the small intestine the radius (r) was calculated
!

(r= •D) to determine the circumference (C) (C= 2pr) of the small intestine. Then the perimeter
"

of the villi exposed to the lumen (PV) (PV= (2•length) + width), the number of villi within the
circumference (VC) (VC=

$%&$'()&*+$*
,%--% .%/012345$* 6*0.**+ ,%--%

), and the surface area of villi exposed to

the lumen (SAV) (SAV= VC•PV) were calculated to calculate the total surface area (SA) per
section of intestine. All measurements were taken in µm and had to be converted to millimeters
(mm) for the calculation of SA (SA=SAV•length of small intestine section). To calculate the
approximate length of each small intestine section, the total length of the small intestine was
divided by three.
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Figure 2; Histological measurements. A) Line 1 depicts how villi length was measured, line 2
depicts how crypt depth was measured, line 3 depicts how the space between the villi were
measured, and line 4 depicts how villi width was measured. B) Line 5 depicts how diameter was
measured.
Immunofluorescence
Glass slides were cleaned with an alcohol acid mix (1% HCl, 70% ethanol) and coated
with 50µl of poly-L-lysine (0.1% aqueous solution, MW >70,000 from Electron Microscopy,
Sciences). Tissues were cut into 5 um sections and placed in a 45°C water bath before adhering
to the poly-L-lysine coated slides. The slides dried overnight and were deparaffinized in xylene
(2x5 mins each), dehydrated/rehydrated in ethanol (100% 2x3 mins, 95% 1 mins, and 80% 1
mins), and then rinsed in deionized water. The slides went through an antigen retrieval process
in a hot water bath with sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0)
at 95-100°C for 20 minutes. After 20 minutes the heat was turned off and the slides cooled to
room temperature while remaining in the sodium citrate buffer for approximately 20 minutes.
The slides were then submerged in PBS Tween 20 (1X PBS, 0.1% Tween 20) 2x2 minutes each.
Slides were blocked with BSA (1%BSA, 1X PBPS) for an hour before incubating with Ki-67
(D3B5 Rabbit mAb Alexa Fluor® 488 Conjugate #11882, Cell Signaling Technology) and DAPI
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(#422801, BioLegend) mix (0.5% Ki-67, 0.000267% DAPI, 1% BSA, 1X PBS) in a humidity
chamber overnight at 4°C. The slides were rinsed with PBS Tween 20 (1X PBS, 0.1% Tween
20), cover slipped using Aquamount mounting media, and stored at 4°C. 20X magnified images
were captured using Ziess Axio Imager M2 with fluorescence provided by X-Cite series 120Q.
Ki-67 staining was quantified using ImageJ. The protocol was as follows: begin with the
merged image and separate the Ki-67 image, take the Ki-67 stained image as a .tif file and
convert it to an 8-bit black and white image, adjust the threshold to create a binary image, and
lastly select the area to be measured. Only whole crypts were analyzed and the number of Ki-67
stained positive cells were calculated per crypt (Figure 3).

A

B

C

D

E

Figure 3; Ki-67 qunatification. A) The merged image with both DAPI and Ki-67
Staining. B) Ki-67 staining. C) Converted to an 8-bit image. D) Converted to a binary image. E)
Crypts to be analyzed are outlined in red.
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Statistics
Statistical procedures used for analysis of data from: spleen weight, dietary intake,
anthropometric measurements, villus length, crypt depth, surface area, and Ki-67 positively
stained cells were performed in GraphPad Prism version 7. One way ANOVAs and t-tests were
performed and data are presented as means ± SD. P-values less than 0.05 were considered
statistically significant.
RESULTS
Spleen Weight Confirms the Action of Glucocorticoids
The effectiveness of glucocorticoid therapy was established by the reduction of spleen
weight, a known effect of glucocorticoids.89 There was a significant difference in spleen weight
in the control group between Chow GC- and Chow GC+ (Chow GC- 0.07193 ± 0.004556, n=6
vs Chow GC+ 0.05966 ± 0.002825, n=7; p=0.0375) demonstrating glucocorticoid efficacy
(Figure 4).
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Figure 4; Spleen weight. Groups: Chow GC+ (n=7) Chow GC- (n=6), HFL GC+ (n=10), HFL
GC- (n=10), HFO GC+ (n=10), and HFO GC- (n=10). All values are mean ±SD.
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Weight Gain Differs Between HFL and Chow Groups
Mice consuming a HFL diet, regardless of GCs, gained more weight over the 4-week
experiment than their Chow and HFO fed counterparts (Figure 5A). Additionally, no significant
differences in weight gained were identified between HFO and Chow groups, despite the dietary
differences in energy density [(HFO 45% fat, 4.72kcal/g) vs. (Chow 6% fat, 3.2kcal/g)].
However, statistically significant differences in total weight gain were detected between Chow
GC- and HFL GC- (Chow GC- 2.753 ± 0.4992, n=8 vs HFL GC- 7.182 ± 1.021, n=10;
p=0.0001), Chow GC+ and HFL GC+ (Chow GC+ 2.024 ± 0.3057, n=8 vs HFL GC+ 5.515 ±
0.485, n=10; p=0.003), and HFL GC- and HFO GC- (HFL GC- 7.182 ± 1.021, n=10 vs HFO
GC- 3.536 ± 0.4539, n=10; p=0.0009) (Figure 5B).
Considering the differences in weight gain, we examined average daily food consumption
and found that the Chow groups ate significantly fewer calories compared to the HFL groups
[(Chow GC- 10.15 ± 0.4438, n=4 vs. HFL GC- 14.16 ± 0.8954, n=10; p=0.0122) (Chow GC+
10.35 ± 0.5847, n=5 vs HFL GC+ 13.64 ± 0.5281, n=10; p=0.0357)] (Figure 5C). Interestingly,
even though there are significant differences in weight gain and food consumed when weight
gained was normalized per kcal consumed, the HFL groups gained more weight per kcal
consumed than both the Chow and HFO mice. The only significant difference was for HFL GCwhich gained more weight per kcal consumed than HFO GC- (HFL GC- 0.01848 ± 0.002494,
n=10 vs HFO GC- 0.01012 ± 0.001249, n=10; p=0.0116) (Figure 5D).
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Figure 5; Weight gain and food consumption over the GC treatment period. A) Groups for
A, B, E: Chow GC- (n=8), Chow GC+ (n=8), HFL GC- (n=10), HFL GC+ (n=10), HFO GC(n=10), HFO GC+ (n=10). Significance was present starting at week 2: HFL GC+ vs HFO GC+,
week 3: Chow GC- vs HFL GC-, Chow GC+ vs HFL GC+, week 4: Chow GC- vs HFL GC-,
Chow GC+ vs HFL GC+, HFL GC- vs HFO GC-, and HFL GC+ vs HFO GC+. B) Significant
differences were observed between: CH GC- vs HFL GC-, CH GC+ vs HFL GC+, and HFL GCvs HFO GC- groups. C) Groups for C and D: Chow GC- n=4, Chow GC+ n=5, HFL GC- and
HFL GC+ n=10, HFO GC- and HFO GC+ n=10. HFL GC+ and HFL GC- ate significantly more
kcals compared to Chow GC+ and Chow CG- groups. D) Weight gain at week four of
intervention was divided by the amount of kcals consumed. HFL groups gained more weight per
kcal consumed compared to Chow and HFO groups. Significance was present between HFL GC
– and HFO GC – groups. E) Visceral adipose tissue, represented by the epididymal fat pads,
were weighted at sacrifice. Significance was present between: Chow GC – vs HFL GC -, Chow
GC + vs HFL GC +, HFL GC – vs HFO GC -, and HFL GC + vs HFO GC +. All values are
mean ±SD.
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Glucocorticoids Have No Effect on Small Intestine Length
Small intestine length was not altered by GC administration but significant differences
were detected between the following: Chow GC- was longer than HFL GC- (Chow GC- 35.5 ±
0.9747 n=5 vs HFL GC- 30.42 ± 1.062, n=11; p=.0117), Chow GC+ was longer than HFL GC+
(Chow GC+ 35.64 ± 1.423, n=5 vs HFL GC+ 30.06 ± 0.8438, n=13; p=.0054), and HFO GC+
was longer HFL GC+ (HFO GC+ 33.79 ± 0.4864, n=12 vs HFL GC+ 30.06 ± 0.8438, n=13;
p=.0196) (Figure 6A). Since glucocorticoids did not affect small intestine length, we examined
small intestine length by diet only. This revealed that Chow mice had a significantly longer
small intestine than HFL mice (Chow 35.57 ± 0.8134, n=10 vs HFL 29.89 ± 0.5844, n=23;
p<.0001) and HFO mice had a significantly longer small intestine than HFL mice (HFO 33.53 ±
0.4673, n=19 vs 29.89 ± 0.5844, n=23; p<.0001) (Figure 6B). This dietary effect on intestine
length appears to be age dependent as we examined the small intestine length in 20-week-old
mice that consumed the same Chow and HFL diets starting at 12 weeks of age for 8 weeks, and
observed no difference between groups in small intestine length (Chow 34.62 ± 1.035, n=10 vs
HFL 34.61 ± 0.6111, n=9; p= 0.9944) (Figure 6C).
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Figure 6; Small intestine length. A) Groups: Chow GC- (n=5), Chow GC+ (n=5), HFL GC(n=11), HFL GC+ (n=13), HFO GC- (n=7), HFO GC+ (n=12). Significance present between:
Chow GC- vs HFL GC -, Chow GC+ vs HFL GC+, and HFL GC+ vs HFO GC+. The presence
of GC did not affect small intestine length. B) Groups: Chow (n=10), HFL (n=23), and HFO
(n=19). Small intestine was examined by diet only and significance was present between: Chow
vs HFL and HFL vs HFO. C) Groups: Chow (n=10) and HFL (n=9). 20-week-old mice,
consuming Chow and HFL between week 12 and 20, show no difference in small intestine length
between diets. All values are mean ±SD.
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Glucocorticoids Preferentially Induce Apoptosis in HFO Fed Mice
While no significant differences were detected among the groups, there were trends. In
the duodenum, Chow GC+ had slightly longer villi than Chow GC- (Chow GC+ 506.2 ± 17.14,
n=2 vs Chow GC- 431.8 ± 24.9, n=3; p= 0.9985) with HFL GC+ (HFL GC+ 515.4 ± 21.19, n=7
vs HFL GC- 500.5 ± 6.776, n=7; p >0.9999) groups following the same trend to a smaller
degree. HFO groups showed a decreased villus length in the presence of GC (HFO GC+ 475.6 ±
193.5, n=2 vs HFO GC- 583 ± 72.51, n=3; p=0.9540) (Figure 7A and 8).
The jejunum had decreased villus length in both Chow GC+ and HFO GC+ groups
compared to Chow GC- and HFO GC- [(Chow GC+ 249.2 ± 42.33, n=2 vs Chow GC- 287.1 ±
26.49, n=3; p= 0.9796) (HFO GC + 245.1 ± 1.849, n=2 vs HFO GC- 365.8 ± 35.6, n=3; p=
0.2732)]. Interestingly, the HFL groups did not follow this pattern as HFL GC+ had increased
villi length compared to HFL GC- (HFL GC+ 335.9 ± 22.34, n=7 vs HFL GC- 295.7 ± 25.34,
n=7; p=0.7976) (Figure 7B and 8). Glucocorticoids had the most defined trend in the ileum,
where the length of villi was decreased with GC, regardless of which diet consumed (Figure 7C
and 8). It appears that HFO GC- vs HFO GC+ had the largest discrepancy in villus length with
the presence of GC throughout the duodenum, jejunum, and ileum compared to both Chow and
HFL groups. When looking at villus length by diet only there is a definitive trend of the longest
villi in the duodenum and decreasing moving into the ileum (Figure 7D and 8). When examining
the 20-week-old mice, there were no differences between the villi length of the Chow or HFL
groups in the ileum (Figure 7E).
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Figure 7; Villi length. Groups: Chow GC– (n=3), Chow GC+ (n=2), HFL GC- (n=7), HFL
GC+ (n=7), HFO GC- (n=3), HFO GC+ (n=2). A) Duodenum villi length had no significant
differences however, HFO GC- had the longest villi and the largest change in villi length when
exposed to GC. B) Jejunum villi length had no significant differences however HFO GC- had the
longest villi and largest change in villi length when exposed to GC. C) Ileum villi length had no
significant differences and the villi length across diets became very similar without GC. HFO
GC+ still has the largest decrease in villi length compared to HFO GC-. D) Groups: Chow
(n=5), HFL (n=14), HFO (n=5). Villi length by diet reveals the trend of the longest villi in the
duodenum and the shortest villi in the ileum regardless of diet. E) Groups: Chow (n=5) and HFL
(n=5). Villi length in 20-week-old mice. All values are mean ±SD.
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Figure 8; Hematoxylin and eosin stained small intestine sections. Hematoxylin and eosin
stained small intestine sections were captured from each group (Chow GC-, Chow GC+, HFL
GC-, HFL GC+, HFO GC-, and HFO GC+) from each part of the small intestine (duodenum,
jejunum, and ileum) at 10X magnification. Note the decreasing villi length from duodenum to
ileum.
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Jejunum and Ileum Crypt Depth is Lost in HFL and HFO Diets
The differences in villi length are thought to be linked to the proliferation of intestinal
stem cells within the crypts which is why we assessed crypt depth throughout the small intestine.
In the duodenum, there were minimal differences in crypt depth with Chow groups having
deeper crypts than both high fat diet groups, regardless of GC. The only significance detected in
crypt depth was between HFL GC+ and HFO GC+ (HFL GC+ 66.95 ± 3.017, n=7 vs HFO GC+
97.29 ± 3.318, n=2, n=7; p=.0425) (Figure 9A).
In the jejunum, HFL and HFO crypt depth were the same regardless of GC presence. A
significant difference was detected between Chow GC- and HFL GC- (Chow GC- 107 ± 4.639,
n=3 vs HFL GC- 69.89 ± 6.365, n=7; p= 0.0075) (Figure 9B). In the ileum, Chow GC- mice had
significantly deeper crypts than HFL GC- mice (Chow GC- 74.93 ± 4.331, n=7 vs HFL GC74.93 ± 4.331, n=7; p=.0054), with Chow GC+ and HFL GC+ (Chow GC+ 107.6 ± 13.61, n=2
vs HFL GC+ 68.55 ± 7.178, n=7; p=.0054) following the same trend (Figure 9C).
When assessing crypt size by diet only there is a definitive proximal to distal decline in
crypt depth for the Chow group. This gradient was not present for both HFL and HFO groups.
Chow jejunum crypts were significantly deeper than HFL jejunum crypts (Chow 100.1 ± 6.188,
n=5 vs HFL 70.73 ± 3.745, n=14; p=0.0017) and Chow crypt depth in the ileum was
significantly deeper than HFL crypt depth in the ileum (Chow 109.5 ± 8.017, n=5 vs HFL 74.93
± 4.331, n=7; p<0.0001) (Figure 9D). Additionally, when the crypt depth of the 20-week-old
mice was assessed in the ileum the HFL crypts were significantly shorter than the Chow crypts
(HFL 68.27 ± 3.673, n=5 vs Chow 91.18 ± 5.61, n=5; p=0.0091) (Figure 9E). This mirrors what
we saw in the younger mice.
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Figure 9; Crypt depth. Groups: Chow GC – (n=3), Chow GC + (n=2), HFL GC – (n=7), HFL
GC + (n=7), HFO GC – (n=3), HFO GC + (n=2). A) Duodenum crypt depth had significance
between HFL GC + vs HFO GC +. HFO had the deepest crypts. B) Jejunum crypt depth had
significance between Chow GC – and Chow GC +. Chow GC + and GC – had the deepest
crypts. C) Ileum crypt depth had significance between: Chow GC – vs HFL GC – and Chow GC
+ vs HFL GC +. Chow GC + and GC – had the deepest crypts. D) Groups: Chow (n=5), HFL
(n=14), HFO (n=5). Crypt depth by diet only had significance between: Chow Jejunum vs HFL
Jejunum and Chow Ileum vs HFL ileum. In Chow, crypt depth increases from duodenum to
ileum. In HFL and HFO, crypt depth decreases from duodenum to ileum. E) Groups: Chow
(n=5) and HFL (n=5). Ileum crypt depth in 20-week-old mice had significance between Chow
and HFL. All values are mean ±SD.
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Surface Area Mirrors Villi Length
Small changes in villus height can equate to total changes in intestinal surface area which
is why we calculated the surface area for the duodenum, jejunum, and ileum. The surface area
mirrored the villi length. There were no significant differences present in the duodenum,
jejunum, or ileum (Figure 10A-C). When examining surface area by diet only, there is a definite
trend of surface area being the largest in the duodenum and decreasing down the small intestine.
Chow and HFL groups are very similar to each other however, HFO has an increased surface
area in the duodenum compared to Chow and HFL groups (Figure 10D).
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Figure 10; Surface area. A) Groups: Chow GC- (n=3), Chow GC+ (n=2), HFL GC- (n=6),
HFL GC+ (n=7), HFO GC- (n=3), HFO GC+ (n=2). Duodenum surface area had no significance
present. HFO GC- and GC+ have the largest surface area. B) Groups: Chow GC- (n=3), Chow
GC+ (n=2), HFL GC- (n=7), HFL GC+ (n=7), HFO GC- (n=3), HFO GC+ (n=2). Jejunal
surface area had no significance present. C) Groups: Chow GC- (n=3), Chow GC+ (n=2), HFL
GC- (n=7), HFL GC+ (n=6), HFO GC- (n=3), HFO GC+ (n=2). Ileum surface area has no
significance present. GC decrease the surface area across every diet. D) Groups: Chow (n=5),
HFL (n=14), HFO (n=5). Surface area by diet shows decreasing surface area from the
duodenum to the ileum. All values are mean ±SD.
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HFL and HFO Diets Have Decreased ICS Proliferation in the Ileum
Ki-67, a proliferation marker present in all active phases of cell cycles (G1, S, G2, and
mitosis), was measured to help explain the differences in villus length, crypt depth, and surface
area. In the duodenum, there were no significant differences between groups (Figure 11A and
12). In the jejunum, there was a decreased amount of Ki-67 staining in both HFL groups
compared to Chow and HFO groups [(HFL GC- 13.21 ± 1.202, n=7 vs Chow GC- 19.53 ± 0.638,
n=3;p= 0.2361) (HFL GC+ 15.2 ± 1.679, n=7 vs Chow GC+ 17.07 ± 0.4085, n=2;p= 0.9903)
(HFL GC- 13.21 ± 1.202, n=7 vs HFO GC- 20.88 ± 1.317, n=3;p=0.0997) (HFL GC+ 15.2 ±
1.679, n=7 vs HFO GC- 24.5 ± 6.627, n=2; p=0.0790)] (Figure 11B and 12).
In the ileum, Chow GC- mice had significantly more Ki-67 stained cells per crypt
compared to HFL GC- and HFO GC- groups [(Chow GC- 27.24 ± 3.764, n=3 vs HFL GC- 13.39
± 1.01, n=7; p<0.0001) (Chow GC- 27.24 ± 3.764 vs HFO GC- 14.31 ± 0.8775, n=3; p=
0.0008)]. Chow GC+ had significantly more Ki-67 stained cells per crypt compared to HFL
GC+ and HFO GC+ [(Chow GC+ 23.38 ± 3.51, n=2 vs HFL GC+ 11.69 ± 0.4528, n=7; p=
0.0018) (Chow GC+ GC+ 23.38 ± 3.51 vs HFO GC+ 13.14 ± 1.238, n=2; p= 0.0359)] (Figure
11C and 12). When reviewing Ki-67 positive cells based on diet alone, the number of Ki-67
stained cells in Chow mice increased from the duodenum to the ileum while in both HFL and
HFO groups there was a decrease present. The ileum of the Chow mice had significantly more
Ki-67 stained cells than HFL ileum and HFO ileum [(Chow ileum 25.69 ± 2.525, n=5 vs HFL
ileum 12.54 ± 0.5819, n=14; p<0.0001) (Chow ileum 25.69 ± 2.525, n=5 vs HFO ileum 13.84 ±
0.6836, n=5; p<0.0001)] and HFL jejunum had significantly fewer Ki-67 stained cells than HFO
jejunum (HFL jejunum 14.2 ± 1.029, n=14 vs HFO jejunum 22.33 ± 2.387, n=5; p=0.0007)
(Figure 11D and 12).
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Figure 11; Ki-67 stained cells per crypt. Groups: Chow GC – (n=3), Chow GC + (n=2), HFL
GC – (n=7), HFL GC + (n=7), HFO GC – (n=3), HFO GC + (n=2). A) Duodenum Ki-67+ cells
had no significance but all GC + groups had increased staining compared to GC – groups. B)
Jejunum Ki-67+ cells had no significance. Chow GC + had less staining than Chow GC -. Both
HFL and HFO groups had increased staining with GC. C) Ileum Ki-67+ cells had significance
between: Chow GC – vs HFL GC -, Chow GC – vs HFO GC -, Chow GC + vs HFL GC +, and
Chow GC + vs HFO GC+. D) Groups: Chow (n=5), HFL (n=14), HFO (n=5). Ki-67+ cells by
diet had significance between: Chow Ileum vs HFL Ileum, Chow Ileum vs HFO ileum, and HFL
Jejunum vs HFO Jejunum. All values are mean ±SEM.
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Figure 12; Ki-67 and DAPI fluorescence stained small intestine sections. Ki-67 positive
stained cells (Green/FITC) with DAPI stained nuclei (Blue) small intestine sections were
captured from each group (Chow GC-, Chow GC+, HFL GC-, HFL GC+, HFO GC-, and HFO
GC+) from each part of the small intestine (duodenum, jejunum, and ileum) at 20X
magnification.
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DISCUSSION, CONCLUSION, RECOMMENDATIONS FOR FUTURE RESEARCH
Discussion
The consumption of a western-type diet leads to DIO promoting chronic low grade
inflammation. This inflammation promotes the development of MS which is a precursor to
T2DM and cardiovascular disease.16-22,61 Research clearly defines the roles of adipose tissue,
liver, and skeletal muscle regarding obesity and MS however, less is known regarding the
GIT.35,36 Since pediatric ALL survivors are at an increased risk for developing obesity and MS
and certain aspects of their treatment, including glucocorticoids and chemotherapeutic agents,
negatively impact the GIT it is vital that we gain a better understanding of how the GIT adapts to
both diet and medications. To our knowledge, there has not been another study that examines
the adaptations of the GIT (duodenum, jejunum, and ileum) in response to different high fat diets
in combination with chronic glucocorticoid dosing in healthy young mice without intestinal
damage. In this study, we introduce novel findings of how high fat diets rich in w-6 or w-3
PUFAs combined with glucocorticoids impact GIT architecture in young mice.
The HFL diet we used in this study mimics the western-type diet in that 45% of the kcals
came from fat, specifically lard, an w-6 PUFA source. The mice fed the HFL diet exhibited DIO
and gained more weight than both Chow and HFO fed mice. The HFO diet had the same amount
of fat as the HFL diet, but from menhaden oil, rich in w-3 PUFAs. The HFL diet promoted
increased adiposity while the HFO mice were protected from this effect as evidenced by the
decreased weight gain and adipose tissue mass compared to the HFL mice.
While there is little known about how dietary intake or glucocorticoids impact small
intestine length, we anticipated that the HFL mice would have the longest small intestine due to
the hyper-proliferative nature of w-6 PUFAs. However, our HFL mice had the shortest small
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intestine. This was surprising as we expected the HFO mice to have the shortest small intestine
due to the anti-mitotic profile of w-3 PUFAs. However, our HFO mice had a slightly longer
small intestine than our HFL mice. Interestingly, Chow mice had the longest small intestine and
glucocorticoids appeared to have no impact on small intestine length across all diets. To date
there is one study that also reported decreased small intestine length on a 60% HFL diet.65
Initially, we believed the reason for these differences was a lack of fiber in the HFL and
HFO diets compared to the Chow diet. We also investigated if the HFL diet increased the
absorptive area resulting in decreased small intestine length, but this also proved to be false.
Importantly, when we assessed the small intestine length in 20-week-old mice there were no
differences across Chow and HFL diets. This led us to believe that there must be age dependent
developmental difference of the impact that HFL and HFO diets have on small intestine length.
There was an increased villus length in the duodenum of mice on the HFO GC- diet
compared to both Chow and HFL groups which is interesting as there were no changes in Ki-67
staining per crypt. We believe this is due to EPA and DHA’s ability to increase cell
differentiation especially since the crypt depth was not different between Chow, HFL and HFO
GC- mice. However, the HFO GC+ mice experienced a decreased villi length compared to both
Chow and HFL groups. With no differences in Ki-67 staining present and a slightly deeper
crypt, it is thought that glucocorticoids are inducing apoptosis with the HFO diet or there is a
block of cell differentiation and migration from the crypt to the villi.
In the jejunum, HFO GC- mice also had increased villus length compared to Chow and
HFL GC- groups with no differences in Ki-67 stained cells per crypt. However, the HFO GCmice had a decreased crypt depth compared to Chow. This indicates that as in the jejunum, EPA
and DHA are increasing cell differentiation that is driving the increased villus length in HFO
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GC- mice. There is also a decreased villus length when glucocorticoids are given to HFO mice.
HFO GC+ mice have decreased crypt depth and increased Ki-67 staining when compared to
Chow groups indicating that increased apoptosis or a block of cell differentiation and migration
from the crypts to the villus is present.
In the ileum, there was a decreased amount of Ki-67 stained cells as well as crypt depth
in both high fat diet groups compared to the Chow group regardless of GC. Additionally, there
were no changes in villus length across the GC- groups. As the Chow diet is indicative of
normal GIT function and morphology, we believe that cells are proliferating at increased levels
but are not differentiating and migrating from out of the crypt. This difference may be driven
due to dietary differences such as decreased fiber intake in the high fat diets. Fiber can be
metabolized by the microbiome to form SCFAs which impact cell proliferation.
Many the current studies on w-3PUFAs anti-mitotic impact are done in models of
intestinal damage such as gastric ulcers or colon cancer which amplifies the anti-mitotic effect of
EPA and DHA in the GIT.69 Multiple studies have outlined EPA and DHA’s negative effect on
wound healing and while GCs don’t create wounds in the GIT they do increase apoptosis which
impacts GIT homeostasis. This may explain the impact that GCs had on our HFO GC+ mice as
well as indicate that without intestinal damage present, w-3 PUFAs are beneficial to GIT
homeostasis due to a more balanced ratio between w-6 and w-3 PUFAs. It is important to note
that EPA and DHA increase cell differentiation which may alter the ratio of enterocytes,
enteroendocrine cells, goblet cells, and Paneth cells in the GIT.69 It is not known what impact
EPA and DHA have on these cell populations but if they are unbalanced it could impact
absorption, mucous secretions, intestinal hormone regulation, and ISC proliferation.
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While our HFL diet may not have supported an increase in villi length, the HFL diet does
protect against GC induced apoptosis, which may be related to increased amounts of B-catenin,
Wnt signaling, COX2, and PGE2. While we did not assess the levels of B-catenin, COX2, or
PGE2 we believe that they would be mildly elevated in both HFL groups resulting in this
protective effect. One reasons our mice may have not exhibited this increased villus length is the
percentage of fat in the diet at 45%, compared to others who use 60%.62
Conclusions
A diet rich in w-3 PUFAs has the biggest impact on the proximal intestine (duodenum
and jejunum) and our data suggest that w-3 PUFAs increase cell differentiation and villi length.
Importantly, the cells increased by w-3 PUFAs appear to be more sensitive to glucocorticoids.
The chow diet had a big effect in the ileum indicated by increased Ki-67 staining and crypt depth
compared to both high fat diets (HFL and HFO). This is potentially due to increased fiber
content of the Chow diet as fiber can be metabolized to SCFAs and impact cell proliferation.
Additionally, a 45% HFL diet rich w-6 PUFAs does not does not alter small intestinal
morphology, however, there was decreased glucocorticoid sensitivity compared to the w-3 PUFA
induced cells. Thus, diets rich in w-3 PUFAs have great metabolic effects and increase intestinal
cell differentiation and possibly proliferation in a healthy GIT. However, our data suggests that
the w-3 PUFA diet induced intestinal cells are more sensitive to the effects of glucocorticoids
and caution should be taken when consuming dietary 8-3 PUFAs when taking high doses of
glucocorticoids.
Suggestions for future research
For future research, we recommend preforming additional immunofluorescent staining
for Paneth cells, goblet cells, enteroendocrine cells, ISCs, enterocytes, TNF-a, b-catenin, COX2,
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PGE2, PGE3, tight junction proteins. This information would provide a better understanding of
the mechanisms behind how w-6 and w-3 PUFAs with GCs modify the GIT.
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APPENDIX

IACUC PROTOCOL ACTION FORM
To:

Marie van der Merwe

From

Institutional Animal Care and Use Committee

Subject

Animal Research Protocol

Date

September 2, 2014

The institutional Animal Care and Use Committee (IACUC) has taken the following action
concerning your Animal Research Protocol No.
0749 Effect of a dietary intervention on
glucocorticoid-induced metabolic syndrome
Your protocol is approved for the following period:
From:

September 2, 2014

To:

September 1, 2017

Your protocol is not approved for the following reasons (see attached memo).
Your protocol is renewed without changes for the following period:
From:

To:

Your protocol is renewed with the changes described in your IACUC Animal Research Protocol
Update/Amendment Memorandum dated
for the following period:
From:

To:

Your protocol is not renewed and the animals have been properly disposed of as described in your
IACUC Animal Research Protocol Update/Amendment Memorandum dated
___________________________________________
Amy L. de Jongh Curry, PhD, Interim Chair of the IACUC

Dr. Karyl Buddington, University Veterinarian
And Director of the Animal Care Facilities
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IACUC PROTOCOL
FOR USE OF LIVE VERTEBRATES FOR RESEARCH, TEACHING OR DEMONSTRATION
UNIVERSITY OF MEMPHIS
IACUC Protocol # 0749

Date Submitted to IACUC 7/21/14

Dates Protocol will be in effect:
from 9/2/14
(not to exceed three years including two yearly renewals)

to 9/1/17

Is this protocol related to an external grant or contract application?

Yes

No X

If yes, complete the following:
Agency:

Date Submitted

Grant #
University account for Animal Care Facility per diem charge:
If the protocol is not related to an external grant or contract application, complete the
following:
University account for Animal Care Facility per diem charge: 211700
Project Title: (If project relates to a grant or contract application, give that title; if the project is
related to a class, give the course name and number):
Effect of a dietary intervention on glucocorticoid-induced metabolic syndrome.
I.

Personnel

Investigator/Instructor: Marie van der Merwe
Department:

Health and Sport Sciences

Academic Rank:

Assistant Professor

Campus phone: 901 678 3476

Emergency phone: 901 406 7458

Attending Veterinarian: Karyl Buddington
Phone:

901 678 2359

Emergency phone: 901 258 1232
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List all individuals that will handle animals using this protocol and their level of expertise (e.g.
relevant qualifications). If the protocol applies to a class then so specify.
Marie van der Merwe – PhD (Molecular Pharmacoly), Postdoctoral Fellowship (Bone Marrow
Transplantation): More than 10 years of experience using mice as a research model.
Simone Godwin – BA (Anthropology), Animal husbandry internship at Duke Lemur Center
(Durham), Primate conservation and rehabilitation internship at Alouatta Sanctuary (Panama)
LeeAnna Beech – B.S (Dietetics), A.S (Science), Animal trainer certification at Dolphin Quest
(O’ahu)
If additional personnel become involved in handling animals used in this protocol, it is the
responsibility of the principal investigator to notify the Animal Care Facility in writing
before they start.
If applicable, has the investigator/instructor and all personnel listed above
received the appropriate vaccinations (tetanus, rabies)?
Yes

No

Is it necessary for personnel listed on this protocol to be tested for TB?

No X

Yes

If you have questions about the kind of vaccination or about TB, call the Animal Care
Facility at 678 2034.
All U of M personnel involved in this protocol must complete the animal care and use
training program (satisfactory completion of, or concurrent registration in Biol 7006/8006),
or have completed a comparable training program at another institution before animals
can be procured or before the experiments/teaching or demonstration. In submitting this
protocol, I, as Principal Investigator/Instructor accept the responsibility for compliance
with this requirement.
In addition, the Principal Investigator/Instructor must be willing to provide appropriate
supervision for all persons working on this protocol. In the case of a class, the Instructor
must be responsible for training any students in classes involved prior to using animals.
II.

Project Description

A.

Summary (Enter a brief description below of your project, using lay terminology):
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Acute lymphoblastic leukemia (ALL) treatment increases the risk for pediatric patients to develop
obesity and symptoms similar to metabolic syndrome including type-2 diabetes and dyslipidemia.
The treatment includes many chemotherapies and also high doses of glucocorticoids. The long
term use of glucocorticoids has been associated with the increases in weight and also symptoms
similar to metabolic syndrome. The goal of this experiment is to determine if dietary interventions
can reduce risk and long term consequences associated with the use of glucocorticoids.
We will use a mouse model (C57BL/6) that will receive a 45% fat (lard) diet, similar to a Western
diet. Control mice will be on a “normal” 10% fat diet. As an intervention, the fat source will be
altered to a 45% fish oil diet (omega-3 fatty acids). Omega-3 fatty acids have been shown to
reduce inflammation and decrease risk of development of glucose intolerance. While on the
various diets, mice will be given the glucocorticoid, prednisone at a dose of 40mg/m2/day for 28
days. Prednisone will be administered orally using a vehicle on a daily basis. 28 days reflect the
induction phase of ALL treatment during which time the patients receive high doses of prednisone
and experience a dramatic increase in weight.
Eating habits (amount of food consumed) and weights of mice will be monitored twice a week.
After two weeks (14 days), half of each group of mice will be anaesthetized to perform a DEXA
scan (whole body fat composition) Blood will be drawn to determine glucose and insulin levels. A
glucose tolerance test will be performed by administering glucose and then measure glucose levels
in blood at various time points. The mice will be sacrificed to harvest brain, adrenal glands, liver,
spleen, mesenteric lymph nodes and adipose tissue for analysis. The remainder of the mice will go
through the same process at 28 day after the start of glucocorticoid treatment.
B.

Describe IN DETAIL the procedures you will follow. You may do this in either of two
ways (Check one of the options below and follow the associated instructions):

1.

Accompanying documentation (include documentation in box below).
OR

2.

By reference to previously published work (provide a complete bibliographic citation
in the box below, and describe any variations from the published technique).
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X

Mice: C57BL/6 male mice will be used for this study and obtained from breeder pairs that are
bred and housed at the animal facility on the University of Memphis campus.
Diets and treatments: All of the mice will be weaned at 3 weeks of age to the western diet with
45% lard and 41% carbohydrate (20% sucrose, 9% corn starch and 12% Maltodextrin 10). For
Specific Aim 1 the mice will remain on this diet. For Specific Aim 2 the lard component will be
replaced using fish oil at the start of glucocorticoid treatment to provide the long chain omega-3
fatty acids. The diets will be purchased from Research Diets, which has experience in producing
the western diet for rodent studies.
Glucocorticoid therapy: To resemble the age group of ALL patients treated at St Jude, mice will
be 6 weeks of age at the start of glucocorticoid therapy. Mice of this age are comparable to a 4
year old child. The glucocorticoid treatment will last for 28 days. Prednisone (40 mg/m2/day)
will be orally administered on a daily basis by adding it to a vehicle of canned sweet potato or
other canned fruits or vegetables. If the vehicle is not sufficient to mask the taste of prednisone,
we might use prednisolone that is bioequivalent to prednisone, but is more palatable. This might
only be needed for the first couple of doses as the increase of appetite drivel by the glucocorticoid
might drive the consumption of the drug in vehicle. If prednisolone is not efficiently consumed,
we will administer the drug by gavage. Again, this might only be required for the first couple of
days until their appetite increases.
Experimental design:
For Specific Aim 1, 40 male mice will be divided into 2 experimental groups, with all mice fed
the western diet with lard and with or without the addition of the glucocorticoid (GC) treatment
(20/group). Half of each group - 10 mice – will only be treated for 14 days. This group will be
anaesthetized (isoflurane) after a 10 h fast, a DEXA scan performed (anesthetized for 15 min) and
blood collected via the saphenous vein in one of the back legs to determine fasting glucose and
insulin levels and also determine cytokine levels. For the glucose tolerance test, these mice will be
given a 1g glucose/kg body weight intraperitoneally and blood collected every 30 minutes for 90
minutes to measure glucose levels. Mice will then be euthanized (CO2 inhalation) to collect brain,
adrenal glands, liver, spleen, mesenteric lymph nodes and adipose tissue for histology,
biochemistry and immune cells harvest. This data will reveal if there is any early indication of the
metabolic phenotype. The remainder of the mice will remain on the glucocorticoid treatment for
another 14 days at which point this group will be anaesthetized (isoflurane) after a 10 h fast, a
DEXA scan performed and blood collected via the saphenous vein in one of the back legs to
determine fasting glucose and insulin levels and also determine cytokine levels. For the glucose
tolerance test, these mice will be given a 1g glucose/kg body weight intraperitoneally and blood
collected every 30 minutes for 90 minutes to measure glucose levels. Mice will then be euthanized
(CO2 inhalation) to collect brain, adrenal glands, liver, spleen, mesenteric lymph nodes and
adipose tissue for histology, biochemistry and immune cells harvest.
The same experimental approach will be used for Specific Aim 2, except the lard diet will be
replaced by the fish oil based western diet.
Specific Aim Western Diet type
1 (n = 40)
Lard
2 (n = 40)
Fish Oil

Treatment
Plus Glucocorticoid No Glucocorticoid
Plus Glucocorticoid No Glucocorticoid
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C.

Rationale for Involving Animals and the Appropriateness of Species and Number Used.

Indicate (here) briefly the short and/or long-term benefits (to humans and/or other animals) of
this use of animals for research, teaching or demonstration. In addition, state briefly why living
animals are required for this study, rather than some alternative model.
The goal of this experiment is to mimic the metabolic syndrome that is induced in the pediatric
population treated for acute lymphoblastic leukemia. No restriction or dietary advice is currently
given to these patients. We are interested in the kinetics of the onset of the syndrome and also
what role the immune system plays is setting up the environment for the disorder.
The C57BL/6 diet induced obesity (dio) mouse model has been used previously to look at the
effect of excess weight on various organ systems. As we are interested in the interaction between
the immune system and other organs and what role it plays in the onset of metabolic phenotype,
we cannot use isolated cell lines or model organisms such as yeast. Additionally, many reagents
have been developed for the use of mouse tissues, especially antibodies that will be used to
identify immune populations.
There will be 10 mice per group for each time point. This number should be sufficient to
determine statistical significance. (There will also be 16 mice on regular chow to use as controls.)
D.

Do the procedures described in B above, have the potential to inflict more
than momentary pain or distress (this does not include pain caused by
injections or other minor procedures)?
Yes

No X

If yes, please address the following:
I have considered alternatives to procedures that might cause more than momentary or slight
pain/distress, and I have not found such alternatives. As such, I have used one or more of the
following methods and sources to search for such alternatives: (check below each method used)
Agricola Data Base

Medline Data Base

CAB Abstracts

TOXLINE

BIOSIS

Lab. Animal Sci. Journal

Lab. Animals Journal

Lab Animal

Animal Welfare Info Center

ATLA (Alternatives to Laboratory Animal Journal)

Quick Biblio. Series

Lab Animal Welfare Bibliography (QL55L27311988)

"Benchmarks"

"Alternatives to Animal Use in Research, Testing and Education"
Current Contents
CARL
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Direct contact with colleagues (if selected, you MUST document this below)

List search words for the literature search:

What is the length of time that the literature search covers?

III. Animal Use
A.

List all animal species to be used (example below).
Number1 Age2

Species

Sex2

Weight2

Where Housed
(Bldg./Rm#)

Hooded Wistar rats

45

2 months

male

250-350 gm

Psychology Bld./422I

C57BL/6 mice

60

2 months

Male

20-25 gm

Psychology Bld./422I

1

Individuals using ectotherms need to only approximate numbers.
Individuals using fish or other ectotherms need not answer this question.

2

Is any species threatened or endangered?
B.

Yes

No X

Source of animals

X Commercial vendor (Source: Jackson Labs) Female mice will be purchased to breed with male mice
available on the UM campus
X Bred at The University of Memphis

Captured from wild
Transferred from another study (IACUC Protocol Number

)

Donated (Source

)

Tennessee Wildlife Resources Agency
Purchased and supplied by TMGC
Is the supplier a USDA approved source?

Yes
52

No

If not, explain why:
Animals are already in residence at U of M
C.

Will surgery be conducted on animals?

Yes

No

If yes, complete this section:
Non Recovery Surgery
Recovery Surgery
Multiple Survival Surgery (if the latter is checked, complete section F)
Surgeon(s) (Name/Job/Title/Academic Rank)

D.

Location of Surgery (Bldg. & Room #)

Will Anesthetic(s), Analgesic(s), or
Tranquilizing agents be administered?

Yes X

No

If yes, complete this section (example below).
Species & Sex
male Hooded Wistar rats

Agent
sodium pentobarbitol

Dose

Route

50 mg/kg

Performed by
(Name/Title/Academic Rank)

i.p.

Mr. Smith/Research
Technician/B.Sc.

C57/BL6 mice

Isoflurane

2-4%

Inhalation

Marie van der Merwe/ Assistant
Professor
Simone Godwin/Masters Student
LeeAnnaBeech/Masters Student

E.
Will euthanasia be carried out?
If yes, complete this section (example below).
Species & Sex
male Hooded Wistar rats

Agent
sodium pentobarbitol

Dose
150
mg/kg
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Yes X
Route
i.p.

No

Performed by
(Name/Title/Academic Rank)
Mr. Smith/Research Technician/B.Sc.

C57BL/6

CO2

3L/min

Inhalation

Marie van der Merwe/ Assistant
Professor
Simone Godwin/Masters Student
LeeAnnaBeech/Masters Student

If no, describe disposition of animal(s) at conclusion of this study in box below.

F.

Will special housing, conditioning, diets or other conditions
be required?

Yes X

No

If yes, please explain in box below.
Mice will be on special high fat (either lard/fish oil) diets in addition to receiving daily oral
glucocorticoids.

G.

Will animals be removed from the U of M campus at any time?

Yes

No X

If yes, please indicate to where and for how long in box below.

H. If they are to be housed for more than 24 hours outside approved facilities at U of M,
provide a scientific justification in box below.

IV. Toxic and Hazardous Substances
A.

Check off any of the following below that will be used in these experiments?
Infectious agents (Fill out a, b)
Radioisotopes (Fill out a, b, e)
Toxic chemicals or carcinogens (Fill out a, b)
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Recombinant DNA (Fill out a)
Experimental drugs (Fill out a)
Malignant cells or hybridomas (Fill out a, c)
Adjuvants (Fill out a)
Controlled substances (Fill out a, d, e)
For each checked off category, answer the questions indicated below:
a.

Identify the substance(s) and completely describe their use, including how will be injected
or given to the animal(s):

b.

Describe all procedures necessary for personnel and animal safety including biohazardous
waste, carcass disposal and cage decontamination:

c.

If transplantable tumors or hybridoma cells are to be injected into the
animals, have the tissues/cells been tested for inadvertent contamination
by viruses or mycoplasma?
Yes

No

If yes, what was the result (indicate in box below).

d.

In the box below, provide a complete list of these substances, and if their use is not
explicitly explained in the materials already provided, explain their use and role in the
research.

Provide DEA license # covering the use of these substances:
To whom (or what entity) is the license issued?
e. Provide Radioisotope License Number:
To whom is the license issued?
V.

Categories of Animal Experimentation Based Upon Level of Manipulation and Pain:
(check off each category that is applicable to this application)
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X

A.

Animals will be involved in teaching, research, experiments or tests involving no
pain, distress, or use of pain-relieving drugs.

X

B.

Animals will be subject to mild stress only (e.g., food or water deprivation of less
than 24 hours for use in behavioral studies such as operant conditioning; physical
restraint for less than 30 minutes), and will not be subject to surgery, painful stimuli,
or any of the other conditions described below. Procedures described in this protocol
have the potential to inflict no more than momentary or slight pain or distress on the
animal(s)----that is, no pain in excess of that caused by injections or other minor
procedures such as blood sampling.

X

C.

Animals will have minor procedures performed, blood sampling, etc. while
anesthetized.

X

D.

Live animals will be humanely killed without any treatments, manipulations, etc. but
will be used to obtain tissue, cells, sera, etc.

E.

Live animals will have significant manipulations, surgery, etc. performed while
anesthetized. The animals will be humanely killed at experiment termination without
regaining consciousness.

F.

Live animals will receive a painful stimulus of short duration without anesthesia
(behavior experiments with flight or avoidance reactions--e.g., shock/reward)
resulting in a short-term traumatic response. Other examples in this category are,
blood sampling, injections of adjuvants, or drugs, etc.

G.

Live animals will have significant manipulations performed, such as surgery, while
anesthetized and allowed to recover. Such procedures cause post-anesthetic
pain/discomfort resulting from the experiment protocol (e.g., chronic catheters.
surgical wounds, implants) which cause a minimum of pain and/or distress. Also
included are mild toxic drugs or chemicals, tumor implants (including hybridomas).
tethered animals, short-termed physically restrained animals (up to 1 hour),
mother/infant separations.

H.

Live animals will have significant manipulations or severe discomfort, etc. without
benefit of anesthesia, analgesics or tranquilizers. Examples to be included in this
category are: toxicity testing, radiation sickness, irritants, burns, trauma, biologic
toxins, virulence challenge, prolonged: restrictions of food or water intake, cold
exposure, physical restraint or drug addiction. All use of paralytic agents (curare-like
drugs) must be included in this category. Describe any abnormal environmental
conditions that may be imposed. Describe and justify the use of any physical restrain
devices employed longer then 1 hour.

VI. Justifications for Category G Studies and Deviations from Standard Techniques
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Describe in the box below any steps to be taken to monitor potential or overt pain and/or distress
during the course of this study and how such pain or distress will be alleviated. Be as detailed as
necessary to justify your procedure.

VII. Certifications
(By submitting this protocol, I am acknowledging that I comply with the certifications
included in Section VII.) (check one)
X

Animal Use for Research. I certify that the above statements are true and the protocol
stands as the original or is essentially the same as found in the grant application or
program/project. The IACUC will be notified of any changes in the proposed project, or
personnel, relative to this application, prior to proceeding with any animal experimentation.
I will not purchase animals nor proceed with animal experimentation until approval by the
IACUC is granted.
Animal Use for Teaching/Demonstration. I certify that the information in this application is
essentially the same as contained in the course outline and a copy of the laboratory
exercises using animals is on file in the IACUC office. The IACUC will be notified of any
changes in the proposed project, or personnel, relative to this application, prior to
proceeding with any animal experimentation. I will not proceed with animal
experimentation until approval by the IACUC is granted.

Estimate the cost of maintaining animals used in this protocol based on current per diem charge
at University of Memphis.
Please specify cost per unit of time:

$ 24/day (24c/cage/day)

Specify anticipated total costs for project duration:

$ 1680

As supervisor of this project it is required that you inform your department chair
concerning any animal per diem costs related to this project that are to be paid by the
department.
By submitting this protocol, the Principal Investigator/Course Director indicates that the
following have been considered:
1.
2.
3.
4.

Alternatives to use of animals.
Reduction of pain and stress in animals to the lowest level possible.
The proper needs of the animals with respect to housing and care.
The lowest number of animals used that will give the appropriate experimental results.
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5.
6.
7.

Use of the most primitive species that will give the appropriate experimental results.
Proper training of all personnel in the care and handling of the species used and in the
procedures called for in this protocol before beginning the experiment/teaching or
demonstration.
That this protocol is not an unnecessary repeat of results already in the literature or in the
case of teaching/demonstrations, results that can be demonstrated using models or video
material.

Principal Investigator/Course Director (Type Name)
e-mail address
Date

Marie van der Merwe

mvndrmrw@memphis.edu

7/21/14

Federal Law requires that members of the IACUC be given adequate time to read and review
protocols including any changes or revisions in them.
The University of Memphis IACUC evaluates protocols on a continuous basis. Any protocols or
modifications or renewals to any protocols to be considered at this time must be received by the
Animal Care Facility no later than the end of the second week of the previous month.
Incomplete protocols will be returned to the principal investigator. We will not accept a FAXed
protocol, renewal form or changes to a protocol.
E-mail the completed protocol to Dr. Guy Mittleman (Dept. Psychology):
mailto:<g.mittleman@mail.psyc.memphis.edu>?subject=RE: IACUC Application
January, 2008
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